Global Multiple Sclerosis Therapies Market was valued at USD 23.6 Billion in 2019 and expected to grow with a CAGR 2.5% over the forecast period 2020-2027. Multiple sclerosis is a disease in which immune system eats away at the shielding encompassing of nerves. Multiple sclerosis is an inflammatory medical condition which results in axonal transection, neurodegeneration of the nerve cells of the brain and spinal cord and demyelination. It is devastating disease-causing coordination functions of the body and disruption in communication. Some of the other symptoms are numbness, spasticity, fatigue, cognitive changes, emotional changes, bladder dysfunction and depression. This disease broadly classified in RRMS(Relapsing-remitting Multiple Sclerosis), SPMS(Secondary-progressive multiple sclerosis), PPMS(Primary-Progressive Multiple Sclerosis), and PRMS(Progressive-Relapsing MS). Multiple Sclerosis therapies include counselling, support group, acupuncture and physical therapy. Upsurge in patient population and increase in number of pipeline drugs are key drivers of the global multiple sclerosis therapies market. For instance, as per Statista, the number of pipeline drugs have increased, from 2001, there were 5,995 drugs in the R&D pipeline to 16,181 drugs in the pipeline in 2019. Furthermore, surge in number of patient assistance programs (PAPs) also support in market growth. Despite that, unspecified etiology restrains the market growth over the forecasting period 2020-2027.

The regional analysis of the Multiple Sclerosis Therapies Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. In which, North America dominates the market owing to increase in demand for MS therapeutic products and increase favorable reimbursement policies. However, APAC also participating in market growth due to improved distribution networking of pharmaceutical company in the region.

Key Players in Global Multiple Sclerosis Therapies Market
Abbvie Inc.
Bayer AG
Biogen
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Merck KGAA
Novartis AG
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type:
Immunosuppressants
Immunomodulators
By Route of Administration:
Oral
Injectable
Intravenous
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy

Asia Pacific
China
India
Japan
Australia


Latin America
Brazil
Mexico
Rest of LA
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year 2017, 2018
Base year 2019
Forecast period 2020 to 2027

Target Audience of Global Multiple Sclerosis Therapies Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors